Proteins usually help the body stay healthy, but sometimes they change into harmful versions. The problem isn’t the proteins themselves but how enzymes modify them after production.
One such enzyme is glutaminyl-peptide cyclotransferase, or QPCT for short. This enzyme alters the composition of amyloid-beta proteins by creating pyroglutamate-modified amyloid-beta (pGlu-Aβ). The modified version can become toxic and damage organs.
Earlier, scientists have been trying to eliminate protein plaques. But now, instead of cleaning up damage, scientists want to stop QPCT from creating toxic proteins in the first place. This shift could change how multiple diseases are treated
The Science of QPCT: Why It Matters
QPCT active protein performs a chemical process called cyclization. This changes the structure of proteins and makes them behave differently. When QPCT modifies proteins like amyloid-beta, they become:
- Insoluble: It clumps together and cannot be dissolved.
- Resistant: The body’s natural “recycling” enzymes cannot break it down.
- Toxic: It becomes poisonous to nerve cells.
This creates a “seeding” effect. A small amount of this modified protein acts like a magnet, forcing other proteins to clump together and spreading damage quickly through the tissue.
When the QPCT enzyme creates a modified active protein, that protein becomes “sticky” and misshapen.
- The Magnet: The modified protein has a chemical charge that attracts nearby healthy proteins.
- The Transformation: When a healthy protein touches the “seed,” it also becomes misshapen and sticky.
- The Clump: These proteins link up to form long chains or large bundles called aggregates or plaques.
Primary Therapeutic Target: Alzheimer’s Disease
In Alzheimer’s, pGlu-Aβ is a major problem. It is stickier and more stable than regular amyloid-beta. Because it stays in the brain longer, it kills more neurons.
Currently, Varoglutamstat is considered the lead QPCT active protein inhibitor. This small molecule inhibitor prevents the enzyme from producing pGlu-Aβ. Other monoclonal antibodies targeting QPCT are currently in various stages of development pipelines.
Beyond Neurology: QPCT in Inflammation and Oncology
QPCT-modified chemokines also contribute to inflammation outside the brain
A chemokine called CCL2 (MCP-1) is modified by QPCT into pE-CCL2, which becomes more stable and potent
This causes a problem where too many immune cells stay in one spot. This leads to chronic inflammation, which is linked to many different diseases.
Cancer cells exploit QPCTL (a related enzyme) to modify the CD47 ‘don’t eat me’ signal, helping tumors evade immune detection. QPCT contributes by stabilizing chemokines that recruit suppressive immune cells.
Challenges in QPCT Intervention
Scientists face three main problems when trying to stop QPCT activity to treat diseases.
-
The Brain Barrier
Most drugs cannot pass into the brain. A protective layer called the blood-brain barrier prevents most foreign substances from entering the brain. A drug that is designed to stop this enzyme must be able to pass through this barrier.
-
Choosing the Right Target
The human body also contains another enzyme called QPCTL. This enzyme is almost identical in shape to the QPCT enzyme, though it functions differently. If a drug is not specific enough, it might turn off the wrong active protein. This mistake could cause dangerous side effects in other organs.
-
Timing the Treatment
These drugs are designed to prevent damage, not fix it. This means they have to be given to the patients very early, before they show symptoms of brain damage. If the trial starts too late, the active protein has already caused permanent harm that the drug cannot undo.
Future Outlook
Using combination therapies is a smart way to treat diseases. QPCT active protein inhibitors can be combined with anti-amyloid therapies to fight diseases from two angles.
For example, the drug can eliminate the old waste, and the other drug can prevent the formation of new active protein. This approach is not destructive, as it might seem, as it doesn’t stop all the enzymes’ activity in the body. It selectively inhibits QPCT enzyme activity, preventing the formation of toxic modified proteins.
Targeting QPCT helps the brain, reduces swelling, and may even fight cancer. As scientists learn more, they might find even more uses for this treatment, without hurting healthy parts of the body.
(DISCLAIMER: The information in this article does not necessarily reflect the views of The Global Hues. We make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information in this article.)
Must Read:
- S Jaishankar: Meet Veteran Diplomat Shaping India’s Foreign Policy
- Top 10 Forex Traders in India – Updated Ranking & Insights
- The Media Beacon
- SHIV NADAR: A PHENOMENAL BUSINESS TYCOON
